Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II trial to evaluate the safety and immunogenicity of PF-06482077

Trial Profile

A phase II trial to evaluate the safety and immunogenicity of PF-06482077

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2018

At a glance

  • Drugs PF 06482077 (Primary)
  • Indications Bacterial infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 20 Sep 2018 According to Pfizer media release, the US FDA granted a breakthrough therapy designation to PF 06482077 for the treatment of Pneumococcal infections in adult population. The decision is based on the results of this study.
    • 31 Jul 2018 According to Pfizer media release, the study demonstrated that the vaccine candidate was safe and well-tolerated and induced functional immune responses that could kill all twenty serotypes.
    • 31 Jul 2018 Status changed from recruiting to completed, according to Pfizer media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top